Clinical - genetic characteristics of neuronal ceroid lipofuscinosis type 2 [PDF]
The article is devoted to the issues of diagnosis and therapy of one of the most severe degenerative diseases in children - neuronal ceroid lipofuscinosis (NCL). This is a group of inherited neurodegenerative diseases related to lysosomal storage diseases characterized by regression of psychomotor development, resistant epileptic seizures, vision ...
Guillermo Guelbert, Norberto Guelbert
openaire +5 more sources
Neuronal ceroid lipofuscinosis type 2: an Australian case series [PDF]
AimLate infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare neurodegenerative disorder presenting in children aged 2–4 years with seizures and loss of motor and language skills, followed by blindness and death in late childhood. Initial presenting features are similar to a range of common epilepsies.
Alexandra M Johnson +11 more
openaire +3 more sources
Experience in Diagnosing Neuronal Ceroid Lipofuscinosis Type-2
Introduction: Developmental regression is always an alarming symptom in children as it is an early sign of some genetic disorders, one of which is neuronal ceroid lipofuscinosis (NCL). NCL is a group of rare neurodegenerative disorder caused by accumulation of intracellular ceroid lipofuscin.
Lanny Christine Gultom +1 more
openaire +1 more source
Red flags for neuronal ceroid lipofuscinosis type 2 disease [PDF]
This commentary is on the case series by Dozières‐Puyravel et al. on pages 528–530 of this issue.
Marina Trivisano, Nicola Specchio
openaire +2 more sources
A Case Report on the Challenging Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) [PDF]
Abstract Neuronal ceroid lipofuscinoses (NCLs), also referred as “Batten disease”, are a group of thirteen rare genetic conditions, which are part of the lysosomal storage disorders. CLN type 2 (CLN2) is caused by the deficient activity of the tripeptidyl peptidase I (TPP1) enzyme, encoded by the TPP1 gene, most frequently leading to the classic late ...
Andrea Nunes +7 more
openaire +4 more sources
The diagnostic challenges presented in a patient with neuronal ceroid lipofuscinosis type 2
Neuronal ceroid lipofuscinosis type 2 (NCL2) is a severe, continuously progressive hereditary metabolic disease for which there is an effective enzyme replacement therapy.Purpose. To study the opinions of specialists (pediatric neurologists, neurologists-epileptologists, geneticists) about the obstacles to the early diagnosis of neuronal ceroid ...
E. D. Belousova +2 more
openaire +1 more source
A clinical case of neuronal ceroid lipofuscinosis type 2
Neuronal ceroid lipofuscinoses (NCL, Batten disease) are a group of inherited neurodegenerative diseases characterized by age-related onset, progressive myoclonus epilepsy, visual impairment and progressive intellectual and motor disorders. In all forms of NCL, the pathological autofluorescent lipopigment accumulates in the brain and other tissues. The
L. S. Kraeva +3 more
openaire +3 more sources
A Case with Neonatal-onset Type 2 Neuronal Ceroid Lipofuscinosis: A Novel Mutation
Neuronal ceroid lipofuscinosis (NCL) is a lysosomal storage disorder that causes progressive neurodegenerative disease as a result of storage in neurons and other cells. Late infantile type (NCL Type 2) of NCL, which is the most common neurodegenerative disease in childhood, is characterised by a homozygous mutation in the tripeptidyl peptidase-1 (TPP ...
Ozgun, Uygur +4 more
openaire +3 more sources
Buffy Coat Score as a Biomarker of Treatment Response in Neuronal Ceroid Lipofuscinosis Type 2
The introduction of intracerebroventricular (ICV) enzyme replacement therapy (ERT) for treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease has produced dramatic improvements in disease management. However, assessments of therapeutic effect for ICV ERT are limited to clinical observational measures, namely the CLN2 Clinical Rating Scale, a
Siyamini Sivananthan +5 more
openaire +4 more sources
Inherited metabolic epilepsies–established diseases, new approaches
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley +1 more source

